Craspase Protease Activation Is Sensitive to Oncogenic Single-Nucleotide RNA Mismatches
Dani Feldmann (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences)
Sam P.B. van Beljouw (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences)
Anna C. Haagsma (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences)
Konstantinos Kalogeropoulos (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences, Technical University of Denmark (DTU))
Aswin Muralidharan (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences, TU Delft - Applied Sciences)
Stan J.J. Brouns (Kavli institute of nanoscience Delft, TU Delft - Applied Sciences)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The type III-E CRISPR-controlled protease Craspase is distinguished from other type III systems by its single-subunit RNA-guided protein complex and direct coupling of RNA recognition to protease activation without second messenger signaling, making it an attractive development platform for bioengineering and therapeutics. Here, we identify five positions within the CRISPR RNA (crRNA) of Craspase from Candidatus "Scalindua brodae" (Sb-Craspase) that are sensitive to single-nucleotide mismatches. We leverage these positions to design crRNAs that selectively target clinically relevant single-nucleotide variants (SNVs) in oncogenic RNA transcripts. Using this approach, Sb-Craspase is selectively activated by the "undruggable" KRAS G12D SNV, while the wild-type transcript does not induce protease activation. Collectively, our results establish a framework for designing crRNAs to target clinically relevant SNVs, laying the groundwork for Craspase-based diagnostics and therapeutics against otherwise intractable oncogenic mutations.
help_outline